The team anticipates launching its first clinical diagnostic assay, which will detect targeted, low-frequency genetic mutations in lung cancer, in 2021.
Illumina said the NextSeq 2000 and NextSeq 1000 reduce run costs by up to 50 percent, compared to the NextSeq 550 model, while increasing the data output.
Lexent's NGS assay for monitoring response to treatment and minimal residual disease for solid tumors will eventually run on the Illumina NextSeq 550Dx.
The deals cover Native Antigen's native and recombinant viral and bacterial antigens, antibodies, and immunoassays in certain European and Asian markets.
The joint GenomeWeb/Bank of America survey showed that most respondents had one preferred supplier despite the prevalence of a multitude of online catalogs.
In Science this week: researchers present a computational method for predicting cellular differentiation state from single-cell RNA sequencing data, and more.
